GeneDx Holdings Corp. Selling and Marketing Expense
GeneDx Holdings Corp. (WGS) reported Selling and Marketing Expense of $88.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-02-23
- GeneDx Holdings Corp. selling and marketing expense for the quarter ending 2025-12-31 was $27.13M, a 53.49% increase year-over-year.
- GeneDx Holdings Corp. selling and marketing expense for the quarter ending 2025-09-30 was $23.51M, a 38.09% increase year-over-year.
- GeneDx Holdings Corp. selling and marketing expense for the quarter ending 2025-06-30 was $19.45M, a 17.26% increase year-over-year.
- GeneDx Holdings Corp. selling and marketing expense for the quarter ending 2025-03-31 was $18.32M, a 13.87% increase year-over-year.
- GeneDx Holdings Corp. selling and marketing expense for fiscal 2025 was $88.41M, a 31.22% increase from fiscal 2024.
- GeneDx Holdings Corp. selling and marketing expense for fiscal 2024 was $67.37M, a 10.52% increase from fiscal 2023.
- GeneDx Holdings Corp. selling and marketing expense for fiscal 2023 was $60.96M, a 50.07% decline from fiscal 2022.
- GeneDx Holdings Corp. selling and marketing expense for fiscal 2022 was $122.08M, a 8.28% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $27.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $50.64M derived: sum of 2 quarters · filed 2026-02-23 | $70.09M derived: sum of 3 quarters · filed 2026-02-23 | $88.41M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $23.51M 10-Q · filed 2025-10-28 | $42.96M derived: sum of 2 quarters · filed 2025-10-28 | $61.27M 10-Q · filed 2025-10-28 | $78.95M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2025-06-30 | $19.45M 10-Q · filed 2025-07-29 | $37.76M 10-Q · filed 2025-07-29 | $55.44M derived: sum of 3 quarters · filed 2026-02-23 | $72.47M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2025-03-31 | $18.32M 10-Q · filed 2025-04-30 | $35.99M derived: sum of 2 quarters · filed 2026-02-23 | $53.02M derived: sum of 3 quarters · filed 2026-02-23 | $69.60M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-12-31 | $17.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $34.70M derived: sum of 2 quarters · filed 2026-02-23 | $51.29M derived: sum of 3 quarters · filed 2026-02-23 | $67.37M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $17.02M 10-Q · filed 2025-10-28 | $33.61M derived: sum of 2 quarters · filed 2025-10-28 | $49.70M 10-Q · filed 2025-10-28 | $65.25M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $16.59M 10-Q · filed 2025-07-29 | $32.67M 10-Q · filed 2025-07-29 | $48.23M derived: sum of 3 quarters · filed 2026-02-23 | $64.99M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $16.09M 10-Q · filed 2025-04-30 | $31.64M derived: sum of 2 quarters · filed 2026-02-23 | $48.41M derived: sum of 3 quarters · filed 2026-02-23 | $63.59M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $15.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $32.32M derived: sum of 2 quarters · filed 2026-02-23 | $47.50M derived: sum of 3 quarters · filed 2026-02-23 | $60.96M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | $16.76M 10-Q · filed 2024-10-29 | $31.95M derived: sum of 2 quarters · filed 2024-10-29 | $45.40M 10-Q · filed 2024-10-29 | $74.63M derived: sum of 4 quarters · filed 2024-10-29 | ||||
| 2023-06-30 | $15.18M 10-Q · filed 2024-07-30 | $28.63M 10-Q · filed 2024-07-30 | $57.87M derived: sum of 3 quarters · filed 2024-07-30 | $92.25M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2023-03-31 | $13.45M 10-Q · filed 2024-04-29 | $42.69M derived: sum of 2 quarters · filed 2024-04-29 | $77.07M derived: sum of 3 quarters · filed 2024-04-29 | $109.90M derived: sum of 4 quarters · filed 2024-04-29 | ||||
| 2022-12-31 | $29.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $63.62M derived: sum of 2 quarters · filed 2024-02-23 | $96.45M derived: sum of 3 quarters · filed 2024-02-23 | $122.08M 10-K · filed 2024-02-23 | $134.91M 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $34.38M 10-Q · filed 2023-11-03 | $37.45M 10-Q · filed 2022-11-14 | $67.21M derived: sum of 2 quarters · filed 2023-11-03 | $92.84M 10-Q · filed 2023-11-03 | $103.12M 10-Q · filed 2022-11-14 | $123.48M derived: sum of 4 quarters · filed 2023-11-03 | ||
| 2022-06-30 | $32.83M 10-Q · filed 2023-08-08 | $36.12M 10-Q · filed 2022-08-15 | $58.46M 10-Q · filed 2023-08-08 | $65.67M 10-Q · filed 2022-08-15 | $89.10M derived: sum of 3 quarters · filed 2023-08-08 | $117.25M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $25.63M 10-Q · filed 2023-05-09 | $29.55M 10-Q · filed 2022-05-12 | $56.27M derived: sum of 2 quarters · filed 2023-05-09 | $84.43M derived: sum of 3 quarters · filed 2023-05-09 | $103.00M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $30.65M 10-K · filed 2022-03-14 | $58.80M derived: sum of 2 quarters · filed 2022-11-14 | $77.37M derived: sum of 3 quarters · filed 2022-11-14 | $112.74M 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | $28.15M 10-Q · filed 2022-11-14 | $22.12M 10-Q · filed 2021-11-15 | $46.73M derived: sum of 2 quarters · filed 2022-11-14 | $82.09M 10-Q · filed 2022-11-14 | $69.94M 10-Q · filed 2021-11-15 | $106.03M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $18.57M 10-Q · filed 2022-08-15 | $53.94M 10-Q · filed 2022-08-15 | $77.88M derived: sum of 3 quarters · filed 2022-08-15 | $93.12M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $35.37M 10-Q · filed 2022-05-12 | $59.31M derived: sum of 2 quarters · filed 2022-05-12 | $74.55M derived: sum of 3 quarters · filed 2022-05-12 | $84.72M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $23.94M 10-K · filed 2022-03-14 | $39.18M derived: sum of 2 quarters · filed 2022-03-14 | $49.35M derived: sum of 3 quarters · filed 2022-03-14 | $63.18M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $15.24M 10-K · filed 2022-03-14 | $12.73M 10-Q · filed 2021-11-15 | $25.41M derived: sum of 2 quarters · filed 2022-03-14 | $33.15M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $10.17M 10-K · filed 2022-03-14 | $24.00M derived: sum of 2 quarters · filed 2022-03-14 | ||||||
| 2020-03-31 | $13.83M 10-K · filed 2022-03-14 | |||||||
| 2019-12-31 | $39.35M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |